PMID- 34740548
OWN - NLM
STAT- MEDLINE
DCOM- 20220429
LR  - 20220531
IS  - 1938-0682 (Electronic)
IS  - 1558-7673 (Linking)
VI  - 20
IP  - 1
DP  - 2022 Feb
TI  - The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; 
      Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost 
      Treatments.
PG  - e25-e38
LID - S1558-7673(21)00187-7 [pii]
LID - 10.1016/j.clgc.2021.09.004 [doi]
AB  - High risk prostate cancer (HR-PrCa) is a subset of localized PrCa with 
      significant potential for morbidity and mortality associated with disease 
      recurrence and metastasis. Radiotherapy combined with Androgen Deprivation 
      Therapy has been the standard of care for many years in HR-PrCa. In recent years, 
      dose escalation, hypo-fractionation and high precision delivery with 
      immobilization and image-guidance have substantially changed the face of modern 
      PrCa radiotherapy, improving treatment convenience and outcomes. 
      Ultra-hypo-fractionated radiotherapy delivered with high precision in the form of 
      stereotactic body radiation therapy (SBRT) combines delivery of high biologically 
      equivalent dose radiotherapy with the convenience of a shorter treatment 
      schedule, as well as the promise of similar efficacy and reduced toxicity 
      compared to conventional radiotherapy. However, rigorous investigation of SBRT in 
      HR-PrCa remains limited. Here, we review the changes in HR-PrCa radiotherapy 
      through dose escalation, hypo- and ultra-hypo-fractionated radiotherapy boost 
      treatments, and the radiobiological basis of these treatments. We focus on 
      completed and on-going trials in this disease utilizing SBRT as a sole radiation 
      modality or as boost therapy following pelvic radiation.
CI  - Copyright (c) 2021. Published by Elsevier Inc.
FAU - Mesci, Aruz
AU  - Mesci A
AD  - Radiation Oncology, Juravinski Cancer Centre, Hamilton Health Sciences Centre, 
      Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
FAU - Isfahanian, Naghmeh
AU  - Isfahanian N
AD  - Radiation Oncology, Juravinski Cancer Centre, Hamilton Health Sciences Centre, 
      Department of Oncology, McMaster University, Hamilton, Ontario, Canada. 
      Electronic address: naghmeh.isfahanian@gmail.com.
FAU - Dayes, Ian
AU  - Dayes I
AD  - Radiation Oncology, Juravinski Cancer Centre, Hamilton Health Sciences Centre, 
      Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
FAU - Lukka, Himu
AU  - Lukka H
AD  - Radiation Oncology, Juravinski Cancer Centre, Hamilton Health Sciences Centre, 
      Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
FAU - Tsakiridis, Theodoros
AU  - Tsakiridis T
AD  - Radiation Oncology, Juravinski Cancer Centre, Hamilton Health Sciences Centre, 
      Department of Oncology, McMaster University, Hamilton, Ontario, Canada. 
      Electronic address: theos.tsakiridis@hhsc.ca.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211008
PL  - United States
TA  - Clin Genitourin Cancer
JT  - Clinical genitourinary cancer
JID - 101260955
RN  - 0 (Androgen Antagonists)
SB  - IM
MH  - Androgen Antagonists/therapeutic use
MH  - Dose Fractionation, Radiation
MH  - Humans
MH  - Male
MH  - Neoplasm Recurrence, Local
MH  - *Prostatic Neoplasms/pathology/surgery
MH  - *Radiosurgery/adverse effects/methods
OTO - NOTNLM
OT  - High risk prostate cancer
OT  - Prostate Radiotherapy
OT  - Prostate cancer
OT  - Stereotactic body radiotherapy
EDAT- 2021/11/07 06:00
MHDA- 2022/04/30 06:00
CRDT- 2021/11/06 05:29
PHST- 2021/01/29 00:00 [received]
PHST- 2021/07/08 00:00 [revised]
PHST- 2021/09/27 00:00 [accepted]
PHST- 2021/11/07 06:00 [pubmed]
PHST- 2022/04/30 06:00 [medline]
PHST- 2021/11/06 05:29 [entrez]
AID - S1558-7673(21)00187-7 [pii]
AID - 10.1016/j.clgc.2021.09.004 [doi]
PST - ppublish
SO  - Clin Genitourin Cancer. 2022 Feb;20(1):e25-e38. doi: 10.1016/j.clgc.2021.09.004. 
      Epub 2021 Oct 8.